ClearPoint Neuro's business continues to perform well despite the stock struggling. The drug delivery business is thriving, which should be aided by maturing partner programs and the introduction of ...
ClearPoint's fundamentals remain strong, despite recent stock weakness. Consumables growth and an expectation of 15-20 system placements in 2025 are illustrative of this strength. The introduction of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback